Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aims/Introduction: To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non‐alcoholic fatty liver disease. Materials and Methods: A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks. Body composition was measured using dual‐energy X‐ray absorptiometry. Results: Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction. However, gliclazide treatment produced no significant changes in weight or fat mass, likely because reductions in fat mass were concomitant with increases in lean tissue mass. Blood glucose concentrations and glycated hemoglobin levels improved in all treatment arms; levels of the latter were lower in patients treated with liraglutide and metformin. Serum alanine aminotransferase concentrations decreased in all treatment arms, whereas serum aspartate aminotransferase concentrations were reduced only by liraglutide and metformin. In all patients, weight loss and total, trunk, limb, and android fat mass reductions were positively correlated with decreases in serum alanine aminotransferase and aspartate aminotransferase levels, whereas reductions in waist circumference were positively correlated with lower serum alanine aminotransferase levels. Conclusions: Compared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non‐alcoholic fatty liver disease. Reductions in weight, fat mass and waist circumference favorably affect hepatic function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Insulin action and resistance in obesity and type 2 diabetes
Czech, M. P. (2017) · Nature Medicine · doi:10.1038/nm.4350 · Cited by 1,258
ACG clinical guideline: evaluation of abnormal liver chemistries
Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.517 · Cited by 1,222
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Removal of Visceral Fat Prevents Insulin Resistance and Glucose Intolerance of Aging
Gabriely, I., Ma, X. H., Yang, X. M., Atzmon, G., Rajala, M. W., Berg, A. H., Scherer, P., Rossetti, L., & Barzilai, N. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2951 · Cited by 563
Research works printed but not linked: 18
- 10.2337/dc18-S008 · DOI · Paper page
- 10.1002/oby.21654 · DOI · Paper page
- 10.1111/j.1463-1326.2006.00686.x · DOI · Paper page
- 10.1186/1475-2840-13-36 · DOI · Paper page
- 10.1007/s00592-014-0638-3 · DOI
- 10.1016/j.jacc.2013.06.027 · DOI · Paper page
- 10.1210/jc.2004-1579 · DOI · Paper page
- 10.2337/dc12-2534 · DOI
- 10.1016/j.diabres.2015.04.008 · DOI
- 10.1210/jc.2013-2920 · DOI
- 10.1002/dmrr.2470 · DOI · Paper page
- 10.1111/1753-0407.12555 · DOI · Paper page
- 10.1007/s00125-014-3302-0 · DOI
- Rondanelli M, 2016, Twenty‐four‐week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus, Patient Prefer Adherence, 10, 407
- 10.1016/j.curtheres.2013.10.002 · DOI
- 10.1111/dom.13190 · DOI
- 10.1111/j.1464-5491.2004.01426.x · DOI · Paper page
- 10.1080/00325481.2016.1169894 · DOI · Paper page
Cited by
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Arroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 527
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Kadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
Ida, S., Kaneko, R., Imataka, K., Okubo, K., Shirakura, Y., Azuma, K., Fujiwara, R., & Murata, K. (2021) · Current Diabetes Reviews · doi:10.2174/1573399816666200705210006 · Cited by 85
Jiao, R., Lin, C., Cai, X., Wang, J., Wang, Y., Lv, F., Yang, W., & Ji, L. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16012 · Cited by 60
Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., Gotoh, K., & Shibata, H. (2022) · Medicines · doi:10.3390/medicines9090047 · Cited by 53
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47
Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
Santini, S., Vionnet, N., Pasquier, J., Gonzalez‐Rodriguez, E., Fraga, M., Pitteloud, N., & Favre, L. (2023) · Obesity · doi:10.1002/oby.23596 · Cited by 39
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
“…in individuals with overweight, T2DM, non-alcoholic fatty liver disease (NAFLD), and high cardiovascular risk showed that participants in the liraglutide group (in the daily dose of 1.8 mg) witnessed a substantial reduction in body weight (from 81.1 ± 2.3 kg to 75.5 ± 2.0 kg, P 0.01) [31].”
InfluentialGao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24
Self-citationRen, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70021 · Cited by 9
Metadata
- Authors
- Feng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D.
- Venue
- Journal of Diabetes Investigation
- Publisher
- Wiley
- Published
- 2018-08-16
- Volume
- 10
- Issue
- 2
- Pages
- 399-407
- ISSN
- 2040-1116 (ISSN-L)
- 2040-1124
- OpenAlex
- W2810643620
- Cited by
- 139
- References
- 18
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Natural Science Foundation of China (81570737, 81570736, 81370947)
- Nanjing University (14380296)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.